Drug General Information (ID: DDIFVW1ZLY)
Drug Name			Ketorolac		Drug Info		Salicylic acid (sodium)		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Analgesics				Antiinflammatory Agents
Structure

Mechanism of Ketorolac-Salicylic acid (sodium) Interaction (Severity Level: Major)
Increased risk of GI mucosal injury/bleeding risk Click to Show/Hide Mechanism Graph
Drug Name		Ketorolac				Salicylic acid (sodium)
Mechanism 1		GI mucosal injury/bleeding risk				GI mucosal injury/bleeding risk
Key Mechanism Factor 1
		Factor Name		Gastrointestinal toxicity
		Factor Description		The risk and severity of gastrointestinal toxicity, including inflammation, bleeding, ulceration, and perforation, increases when drugs with gastrointestinal mucosal irritant effects are combined.
Mechanism Description		Increased risk of GI mucosal injury/bleeding risk by the combination of Ketorolac and Salicylic acid (sodium)
Increased risk of nephrotoxicity Click to Show/Hide Mechanism Graph
Drug Name		Ketorolac				Salicylic acid (sodium)
Mechanism 2		Nephrotoxicity				Nephrotoxicity
Key Mechanism Factor 2
		Factor Name		Nephrotoxicity
		Factor Description		The combination of drugs that can induce nephrotoxicity may increase the risk of kidney injury. When kidney injury occurs, the inability to remove excess urine and waste from the body can lead to high levels of urea nitrogen, creatinine, and electrolytes (such as potassium and magnesium) in the blood.
Mechanism Description		Increased risk of nephrotoxicity by the combination of Ketorolac and Salicylic acid (sodium)

Recommended Action
Management		Concurrent use of ketorolac with other NSAIDs or aspirin is considered contraindicated.

References
1	Product Information. Toradol (ketorolac). Roche Laboratories, Nutley, NJ.